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The human immunodeficiency virus type 1 (HIV-1) proteome is expressed
from alternatively spliced and unspliced genomic RNAs. However, HIV-1
RNAs that are not fully spliced are perceived by the host machinery as
defective and are retained in the nucleus. During late infection, HIV-1
bypasses this regulatory mechanism by expression of the Rev protein
from a fully spliced mRNA. Once imported into the nucleus, Rev mediates
the export of unprocessed HIV-1 RNAs to the cytoplasm, leading to the
production of the viral progeny. While regarded as a canonical RNA
export factor, Rev has also been linked to HIV-1 RNA translation, stabiliz-
ation, splicing and packaging. However, Rev’s functions beyond RNA
export have remained poorly understood. Here, we revisit this paradig-
matic protein, reviewing recent data investigating its structure
and function. We conclude by asking: what remains unknown about this
enigmatic viral protein?1. Introduction
Human immunodeficiency virus (HIV-1) is a retrovirus that infects CD4+
T-lymphocytes and macrophages, leading to a gradual loss of CD4+ cells and
subsequent immunodepression termed acquired immunodeficiency syndrome
(AIDS). HIV infects approximately 37 million people globally and is treated
using life-long anti-retroviral therapy (ART) [1] that suppresses but does not
fully eliminate the virus. Widely used first-line ART include a cocktail of com-
pounds that target the viral enzymes, such as protease, reverse transcriptase
and integrase inhibitors [1]. In the search for new therapies, scientists are
expanding their interest towards other viral and cellular proteins. HIV-1
expresses 15 proteins from a single approximately 9 kb RNA genome (figure 1a)
using two different strategies: the synthesis of polyproteins that are processed
by the viral protease and alternative splicing. HIV-1 RNA is considered fully
spliced when the two large intronic sequences present in the genome are
removed. These fully spliced transcripts leave the nucleus using the canoni-
cal NXF1-mediated pathway for cellular mRNA export [3]. However, the
HIV-1 genome can remain unspliced or undergo a single splicing event,
leading to so-called underspliced HIV-1 RNAs. These underspliced tran-
scripts are retained in the nucleus, in an analogous manner to unspliced
cellular mRNAs [4,5]. To bypass nuclear retention, retroviral underspliced
RNAs harbour regulatory elements that recruit the cellular export machin-
ery either directly or through an adaptor viral protein. For example,
Mason-Pfizer monkey virus (MPMV) RNA harbours a constitutive transport
element (CTE) that allows direct recruitment of TAP/NXF1 export machin-
ery [6]. By contrast, underspliced HIV-1 RNAs contain an RNA structure,
known as the Rev response element (RRE), that recruits the viral export
factor Rev [7]. Rev is expressed from a fully spliced viral RNA and binds
to the RRE to elicit the export of the underspliced viral (v)RNAs to the cyto-
plasm through the recruitment of host factors. The critical roles of Rev in
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Figure 1. (a) Schematic of the HIV-1 genome, which is alternatively spliced. Start sites of open reading frames are numbered according to the NL4-3 HIV-1
sequence. (b) Though Rev is partially structured, it is predicted to be highly disordered at the amino acid level (data obtained from IUPred, where a score of
greater than 0.4 indicates a high degree of disorder) [2]. Despite its disordered structure, Rev structures have been solved; regions indicated are labelled with
Protein Data Base references and coloured for the ARM region ( purple) and additional regions (gold). Post-translational modifications (PTMs) and amino acid
variants obtained from UniProt are shown (main figure based on variant P04325).
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HIV-1 gene expression extend beyond RNA export and
include RNA splicing, stability and translation. How Rev
influences these processes, however, remains poorly
characterized. Research into Rev has been held back by
several technical difficulties, including low expression
levels in infected cells and difficulties in expressing
tagged Rev from the viral genome. Consequently,researchers have been forced to use systems that do not
fully recapitulate physiological HIV-1 infection, often
bypassing infection entirely and using cell lines which
are not naturally infected by HIV-1. Here, we discuss the
functions, structure and protein partners of Rev, examining
both the discrepancies reported across varying experimen-
tal systems and the data commonly unearthed across them
r
3in the light of more recent research. We also discuss which
mysteries of this enigmatic protein remain unsolved.oyalsocietypublishing.org/journal/rsob
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2.1. The architecture of Rev
Rev was discovered through mutations of the overlapping
HIV-1 tat gene, which specifically increased the production
of fully spliced viral RNA and eliminated production of
underspliced transcripts [8]. These effects could not be
reversed by in trans complementation with Tat, suggesting
that they were Tat-independent [9]. They were attributed to
a novel HIV-1 gene, initially termed trs/art, later named Reg-
ulator of expression of virion proteins (Rev). Rev comprises
116 amino acids and is highly disordered (figure 1b). It har-
bours a folded N-terminal domain (NTD) and unstructured
C-terminal domain (CTD). The 65-residue NTD adopts an
anti-parallel helix–turn–helix organization and encodes an
arginine-rich RNA-binding motif (ARM) encompassing a
nuclear/nucleolar localization signal (NLS) and two flanking
oligomerization motifs, which allow Rev to multimerize
(figure 1b) [10]. Indeed, Rev has a high capacity for self-
association and is shown in crystal structures to do so using
three types of homotypic interactions termed A–A, B–B
and C–C interfaces [11–13]. A–A and B–B interactions
occur when same-face α-helices associate in a V motif
(figure 2a) and exhibit some degree of structural malleabil-
ity. C–C pairings occur at the loop ends of α-helices by a
proline interaction and exhibit restricted flexibility [11–
13]. The disordered nature of the Rev CTD has made it
challenging to characterize biochemically and structurally,
although it has been proposed to fold into β sheets in cer-
tain contexts such as filament formation [12,14,15].
Notably, the CTD encodes a leucine-rich nuclear export
signal (NES), sometimes referred to as the ‘activation
domain’. Rev employs its NES and NLS to traverse the
nuclear pore and move between the nucleus and cyto-
plasm. This shuttling ability is critical to allow Rev to
export underspliced viral RNAs and then return to the
nucleus [16].
2.2. Rev specifically exports underspliced viral RNA from
the nucleus
Following reverse transcription, HIV-1 proviral DNA inte-
grates into the host cell genome. Production of HIV-1
RNAs is then mediated by the host RNA polymerase II
giving rise to over 100 different RNA species by alternative
splicing [17]. The approximately 9 kb unspliced genomic
viral RNA encodes Gag and GagPol polyproteins, which
are the structural and enzymatic proteins required for virus
formation and propagation (figure 1a) [18]. The approxi-
mately 4 kb singly spliced species encode for the Envelope
protein as well as the auxiliary factors Vpr, Vpu and Vif,
while the approximately 2 kb fully spliced RNAs encode
for regulatory Tat, Rev and Nef proteins (figure 1a) [18]. In
the early phase of infection, underspliced RNAs are retained
in the nucleus and eventually degraded as they are recog-
nized by the host machinery as ‘immature’ [19]. Conversely,
rev and the other fully spliced mRNAs are exported to the
cytoplasm as they are recognized as ‘mature’ transcripts[3,20]. Once Rev protein is produced, it is imported into the
nucleus by direct interaction with cellular importins β, trans-
portin, importin 5 and importin 7 through its NLS [21,22].
Ribosome assembly factor B23 has been shown to aid in
this import [23,24]. In the nucleus, Rev recognizes specifically
a 351-nucleotide secondary structure present in the second
intron of underspliced (approx. 9 and approx. 4 kb) viral
RNAs, known as RRE [25–33]. Rev interacts with the RRE
with high affinity (reported Kd = 0.3–5 nM), using the argi-
nine residues of the ARM motif aligned in an α-helix which
are projected to and inserted into a major groove in the
RNA (figure 2b) [29,31,34–37]. How Rev assembles on the
RRE remains unclear. Some groups postulate that Rev typi-
cally binds the RRE as a monomer and oligomerizes
thereafter in a cooperative manner along lower affinity sites
[28,31,35,36,38–42]. Other groups suggest that Rev exists as
a multimer in solution and binds the RRE as such, where
gel shift and fractionation experiments show Rev–RRE
interacting at distinct stoichiometries [10,21,29,30,34,43].
Technological advances have led to a series of recent Rev
and RRE structures, which provide clues to Rev–RRE stoichi-
ometry. 3D small-angle X-ray scattering reconstructions show
that the RRE adopts an ‘A-like’ topology [44], where the
primary binding site for Rev on stem loop IIB maps to one
of the ‘A’ legs, and site IA, a posited secondary Rev-binding
site [40,45], maps to the other leg (figure 2c). These sites are
separated by approximately 55 Å, which matches the span
of a Rev dimer [44]. It has been posited that a Rev dimer
first binds the RRE at these sites; when either leg of the ‘A’
shape is removed, the RRE is non-functional, supporting
this model [46]. Similarly, when the ‘crossbar’ of the A is
extended, spanning greater than 55 Å, binding of Rev to
the RRE is strongly impaired [46]. A different model envi-
sions two Rev dimers associating through a C–C interface,
each dimer binding the RRE separately at sites stem IIB
stem IA [12]. This model is supported by a new tetramer crys-
tal structure, which indicates that B–B Rev dimers bind
through C–C interfaces to form tetramers, which bind stem
IIB and IA sites [47]. Nucleotides G47, G48 and A73 in
stem loop IIB of the RRE form non-canonical base pairs
that present a wider groove to facilitate Rev binding. Crystal
structures have identified that these ‘wobble’ pairings prob-
ably help to orient the interaction of a second Rev
monomer, allowing it to reach additional junction sites
along stem II [13]. Accordingly, mutation of these nucleotides
reduces Rev-stem loop IIB interaction, increasing the dis-
sociation constant by over 2 µM in the case of A73 [37].
Regardless, Rev oligomerization appears to be a pre-requisite
for successful RNA export since (i) Rev mutants unable to oli-
gomerize are defective for export [39,43,48,49] and (ii) stem
loop IIB alone is insufficient to trigger RNA export,
suggesting a requirement for oligomerization along low-affi-
nity binding sites [40,50].
After Rev binds the RRE, host cell exportin Chromosome
Region Maintenance Gene 1 (CRM1, also known as XPOI)
and RanGTP are recruited to the Rev NES [51,52]. Rev
appears to interact with CRM1 non-canonically; a recent elec-
tron microscopy structure indicates that when CRM1
interacts with Rev, it does so as a dimer, binding the Rev
NES [53]. Crystal structures show that Rev NES binds
CRM1 in a linear, unorthodox fashion, where the NES is
spaced out using proline residues to reach all five hydro-
phobic binding pockets of CRM1 [54]. It also appears that
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Figure 2. (a) The Rev N-terminal domain is composed of a helix–loop–helix motif and dimerizes in a hashtag motif. An arginine-rich RNA-binding motif is flanked
by oligomerization motifs on both helices, which allow Rev to multimerize. NTD helices are stabilized by core hydrophobic interactions; some contributing residues
are labelled (PDB: 6BSY). (b) A Rev dimer was crystallized in complex with the RRE; Rev binds stem IIB of the RRE using its arginine-rich motif, which makes
contacts with the negatively charged RNA backbone (PDB: 4PMI [13]). (c) The structure of the 351-nucleotide Rev response element; regions are named using
Roman numerals. (d ) The canonical cycle of Rev exporting underspliced viral RNA to the cytoplasm. Rev binds the Rev response element on underspliced RNA
at stem IIB, multimerizes and recruits CRM1 and RanGTP to cross the nuclear pore complex. In the cytoplasm, this complex can dissociate by RanGAP promoting
RanGTP hydrolysis, freeing viral RNA. Rev can re-enter into the nucleus by binding importin-β.
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RRE-bound Rev dimers spatially orient their CTDs to opti-
mally recruit CRM1 [47]. In this RNA-bound state, Rev’s
NLS is occluded while the NES remains accessible, facilitat-
ing CRM1 recruitment and export [21]. It remains poorly
understood if additional host cofactors contribute to Rev/
CRM1-mediated export. However, recent data posit a string
of proteins which may be part of this complex, including
phosphoproteins [55], RNA helicases [56,57], nucleoporins
[58] and additional factors [59–62], some of which will be dis-
cussed in later sections. The Rev-viral RNA–CRM1–RanGTP
complex then traverses the hydrophobic channel of the
nuclear pore and, once in the cytoplasm, disassembles
upon RanGTP hydrolysis. Liberated viral RNAs can then be
translated and Rev can be recycled back to the nucleus by
importin recruitment (figure 2d ), which has been shown to
occur exclusively following RNA dissociation [21]. In this
way, Rev tightly couples the transcription of viral RNAswith their nuclear export, enabling expression of all viral
genes in the right quantities and at the right time.2.3. Rev drives underspliced HIV-1 RNAs towards the
CRM1 export pathway
Rev reduces the levels of cellular and viral RNAs exported by
CRM1-independent pathways by blocking TAP/NXF1, the
main cellular pathway that exports the bulk of cellular
mRNAs. Taniguchi et al. [63] showed that Rev inhibits
TAP/NXF1-specific export of RNAs containing the RRE.
Overexpression of TAP components decreased the levels of
underspliced viral RNA, an effect that could be reversed by
Rev overexpression [63]. This suggests that Rev downregulates
the TAP/NXF1 pathway to bypass cellular checkpoints that
royalsocietypublishing.org/journal/rsob
O
5induce the degradation of underspliced viral RNA. Since fully
spliced viral mRNAs such as rev use TAP/NXF1 to be
exported, accumulation of Rev protein may lead to the sup-
pression of TAP/NXF1 export pathway to increase the ratio
of underspliced to spliced transcripts in the cytoplasm.
Accordingly, Rev was proposed to interfere with the associ-
ation of TAP/NXF1 components, such as ALY/REF, with
RNA [63]. Although the exact mechanism remains unknown,
Taniguchi et al. [63] propose a model by which RNA-bound
Rev may interact with the nuclear cap-binding complex
(CBC) to inhibit its interaction with Aly/REF and sub-
sequently suppress downstream TAP/NXF1 export. Rev can
indeed bind subunits of the nuclear CBC [61], which lends
credence to this model.pen
Biol.10:2003202.4. Rev stabilizes viral RNAs
In addition to stimulating nuclear export, Rev may serve sev-
eral post-transcriptional roles to promote HIV-1 expression.
For example, Rev binding to the RRE appears to overcome
the inhibitory effects of instability (INS) sequences in HIV-1
RNAs. These INS regions have been identified in the env,
gag and pol coding regions and promote nuclear retention,
instability and reduced polysome loading of viral RNA
[64–69], independently of splicing. INS regions are AU-rich,
which confers a different codon usage to that of human
mRNAs [70–72]. The presence of non-optimal codons pro-
motes mRNA instability, likely due to ribosome stalling and
inefficient translation at these sites. The mutagenesis of an
AU-rich INS site in gagpol increases protein expression by
ameliorating steady-state mRNA levels [73,74], illustrating
the effects of these regions and the importance of codon
optimality. High A and low C content produces a codon
bias on HIV-1 RNA that may also decrease protein expression
because of a lack of cognate tRNAs in steady-state cellular
conditions, which induces long ‘waiting times’ for the
ribosome to engage with the correct tRNA [75,76]. Indeed,
circumventing INS sites with codon-optimization was
shown to increase protein expression of HIV-1 Env, indepen-
dently of effects on RNA export or stability [72]. The
Rev–RRE interaction seems necessary to counteract INS-
mediated effects [64–68], since mutations nullifying INS
regions have been shown to switch HIV-1 protein expression
from Rev-dependent to Rev-independent [73,74,77]. How
Rev helps to overcome instability signatures is yet to be fully
elucidated. However, it has been demonstrated that enhanced
expression of codon-optimized gag and pol genes results pre-
dominantly from an increase in cytoplasmic mRNA [74,77].
When cells were pre-treated with leptomycin B, an inhibitor
of Rev–RRE export partner CRM1, expression of Rev-depen-
dent HIV-1 proteins was significantly reduced. Expression of
codon-optimized counterparts, however, was not affected
[76]. This suggests that codon-optimization allows HIV-1
RNAs to use other export pathways, triggering this increase
in cytoplasmic RNA. It is therefore likely that INS regions
cause nuclear retention of HIV-1 RNAs, which Rev–RRE bind-
ing and export is necessary to overcome. It has also been
proposed that certain host proteins can bind AU-rich INS
sequences and that these interactions regulate HIV-1 RNA
stability [78–82]. Rev interacts with some of these cellular fac-
tors and it is plausible that by engaging with them, Rev
interferes with their regulatory activity on HIV-1 RNA. Insummary, Rev emerges as regulator of viral RNA stability by
counteracting the inhibitory effects of INS regions.
2.5. Rev inhibits cellular splicing
Rev may inhibit splicing in an RRE-dependent manner.
The ARM peptide of Rev was found to inhibit splicing of
RRE-containing RNA up to 15-fold more than control RNA
lacking the RRE [83]. Incubation of the Rev ARM with a
β-globin-RRE pre-mRNA at different time points showed
that splicing was only inhibited when Rev was added early,
suggesting that the Rev/RRE interaction interferes with
initial spliceosome assembly on the RNA [83]. Fractionation
and sucrose centrifugation of these splicing extracts revealed
that the addition of Rev to RRE-containing pre-mRNA
removed the 60S peaks corresponding to fully assembled
spliceosomes [83], and caused an accumulation of a 45-50S
splicing-deficient complex. The same group discovered that
the Rev ARM blocked binding of U4/U5/U6 tri-snRNP in
an RRE-dependent manner [84]. While it is not known how
Rev exerts these effects, it may interact with host cell splicing
factors to do so. A recent study used a genome-wide
CRISPR/Cas knock-out approach to identify host cell pro-
teins responsible for HIV-1 RNA nuclear retention. The
majority of the resulting hits were host cell proteins involved
in pre-mRNA splicing and associated with the spliceosome
[85]. Perhaps Rev suppresses formation of the early spliceo-
some by interacting with these factors, ultimately
promoting intron retention. One example of this is SF2/
ASF, an essential splicing factor that binds to RNAs with a
50 splice site to aid U1 snRNP docking [86]. SF2/ASF binds
the Rev-bound RRE in vitro and its overexpression can inhibit
Rev function and HIV-1 gene expression in a dose-dependent
manner [86]. It also regulates HIV-1 gene expression [87–89].
It is plausible that Rev sequesters this splicing factor, and
possibly other spliceosome-associated components, to pre-
vent spliceosome recruitment. Importantly, SF2/ASF
overexpression has been shown to alter the alternative spli-
cing pattern of HIV-1 [90]. Hence, Rev may bind this factor
in infected cells to ensure optimal stoichiometry of HIV-1
RNA forms. At a global level, HIV-1 infection increases the
proportion of introns within cellular RNAs in primary T
cells [91], aligning well with this inhibitory activity of Rev
on SF2/ASF. Collectively, these posited roles paint a picture
of Rev working against host cell regulation to repress splicing
and promote the expression of underspliced HIV-1 RNA.
2.6. Rev promotes translation of viral RNA
It has been proposed that Rev influences the translation
efficiency of viral RNA. Early research highlighted dispropor-
tionate increases in viral Envelope protein expression relative
to total mRNA levels in Rev and Tat-transfected cell lines
[92]. Additional studies confirmed large discrepancies
between cytoplasmic gag mRNA and protein levels in the
absence of Rev [93–96], providing the first clue that Rev
may affect translation. Moreover, Rev appears to facilitate
association of viral RNA with polysomes. One study found
that 90% of cytoplasmic, singly spliced env RNA associated
with monosomes when infected with HIV-1 lacking Rev
(HIV-1Rev(-)), whereas over 75% associated with polysomes
when infected with wild-type Rev HIV-1 [94]. Conversely,
polysomal association with fully spliced viral RNAs such as
royalsocietypublishing.org/journal/rsob
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6tat was unaffected by the presence or absence or Rev, indicat-
ing efficient assembly of ribosomes onto these viral RNAs in
a Rev-independent manner. Interestingly, Rev-dependent
association of underspliced viral RNA with polysomes was
found to be dependent on the presence of the RRE,
suggesting the need of Rev/RRE interaction for this phenom-
enon to occur [93]. However, tethering of the leucine-rich
domain of Rev, which interacts with CRM1, to HIV-1 RNA
allowed efficient Gag production in the absence of Rev, indi-
cating that RNA export is the predominant function of Rev
[97]. These results also suggested that CRM1-mediated
export, instead of Rev itself, may be sufficient to enable
HIV-1 RNA downstream translation through an export/
translation coupling mechanism. Intriguingly, a conserved
Rev-binding site was discovered in the 50 UTR of HIV-1
RNA, overlapping with the loop A of the packaging signal
(SL1) [98]. Rev enhanced the translation of loop A containing
reporters in vitro translation [99]. However, these findings
were not recapitulated by the same group in COS-1 cells
[100]. Whether Rev controls HIV-1 RNA translation remains
ultimately unclear.2.7. Does Rev regulate packaging of HIV-1 genome into
virions?
The presence of a packaging signal in the 50 untranslated
region (UTR) of HIV-1 genomic RNA does not suffice for effi-
cient assembly of the viral RNA into viral particles. The
interaction of Rev with the RRE is also proposed to contribute
to viral RNA packaging [101–104]. The ratio of genomic RNA
in virions over the cytoplasm was measured using an HIV-1
chimeric construct containing the RRE in the presence or
absence of Rev [105]. Lack of Rev induced a decrease in
genome packaging of 10-fold when compared with
conditions where Rev was present [105]. However, the
RRE–RNA construct used in this study lacked the original
INS present in the HIV-1 genome, and thus probably does
not display the same dependency on Rev for nuclear RNA
export as wild-type HIV-1 genomic RNA. The same group,
therefore, repeated this work, using an almost full-length
HIV-1Rev(-) expression plasmid [106]. They reported that
Rev induces a 4500-fold increase in HIV-1 genome packaged
into virions, while it only increases cytoplasmic levels by
5-fold [106]. However, the same enhancement in RNA assem-
bly was observed when a chimeric HIV-1Rev(-) genomic RNA
including MS2 stem-loops was co-transfected with MS2-TAP
[106]. This suggests that is not necessarily Rev, but the export
process itself which boosts the packaging of RNA genomes.
Regardless, Rev–RRE interaction appears to be more efficient
at promoting packaging than TAP, leaving room for potential
direct roles of Rev in packaging [104,105]. The mechanistic
details of how Rev confers increased genome encapsidation
remain unknown. It is possible that certain export pathways
lead to the formation (or avoidance) or specific ribonucleic–
protein complexes which may promote or hinder down-
stream packaging. Indeed, helicase DDX24 has been shown
to directly interact with Rev and increase RNA packaging
only in the context of Rev/RRE export [107].
The Rev-binding site situated in the HIV-1 50 UTR (loop A
of SL1) is also proposed to stimulate viral RNA assembly into
viral particles [98,100,108]. However, recent reports suggest
that HIV-1 RNA is more efficiently packaged as a dimerthan as a monomer [104,109]. Dimer formation required
base pairing across the 50 UTR, including the Gag AUG
start codon and the dimerization initiation site (DIS) [104].
It is thus possible that the loop A, situated between DIS
and the Gag AUG initiation codon, contribute to dimer for-
mation. Therefore, whether the loop A contributes to viral
RNA assembly into viral particles through a Rev-dependent
or independent mechanism remains controversial.
2.8. The Rev–host interactome
HIV-1 cannot encode all the machinery required for its repli-
cation and spread. Thus, it is heavily reliant on host cell
resources. One prevalent strategy used by viruses to hijack
cellular resources is to express viral proteins that interact
with and recruit key cellular factors. By knowing which cellu-
lar factors Rev interacts with, it is thus possible to obtain
deeper mechanistic insights into its regulatory roles. A
common approach for discovering protein–protein inter-
actions (PPIs) globally involves immunoprecipitation (IP)
followed by mass spectroscopy analysis (MS). This approach
has been employed to reveal the interactomes of HIV-1
proteins [110–114]. Few studies have focused on Rev inter-
actions using this approach [111,114–116], and have
enriched our current knowledge of the Rev–host protein
interactome considerably, which to date comprises almost
300 interactors (figure 3) [111,117]. However, a number of
technical limitations forced researchers to use non-physiologi-
cal systems to study Rev, which implies that many of the
interactions identified may not take place when Rev is
expressed at physiological levels and concomitantly interact-
ing with the viral RNA in infected cells (table 1).
Furthermore, the cell system, cofactors, controls, tags and
proteomic quantification used in these studies vary widely.
This is important because even small changes in the exper-
imental conditions can have a profound impact in the
observed interactions. For example, addition of Mg2+ was
recently reported to impact the structural dynamics of the
RRE and potentially Rev binding [118]. It has also been
found that the importin which mediates Rev nuclear import
is cell-type specific and will therefore differ between cell sys-
tems [119], which may impact downstream Rev function. It is
difficult, as a result, to collate published datasets obtained by
employing different systems. Another important problem
regarding interactome analysis is the quantitation, controls
and statistical analysis of proteomics data. The lack of a uni-
versal, standardized data analysis pipeline and the
differences in experimental set-up makes it extremely difficult
to compare different datasets. The limitation of self-defined
scoring is that results depend somewhat on arbitrary assign-
ments for significance. For example, one study identified only
19 overlapping protein–protein interactions between their
results and VirusMint, a database of virus–host cell PPIs,
but this increased to 67 when the MS processing threshold
score was altered [114]. Such subjective quantitation par-
ameters are problematic when cross-referencing large
datasets produced by different groups. As a result of these
obstacles and differing IP systems, overlap between reported
Rev interactors is limited (figure 4) [59,114,116,121,122]. The
lack of overlapping can also be explained by the expression
of Rev in non-physiological levels and outside the natural
infection context. To circumvent these limitations, future
work should focus on the biochemical characterization of
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Figure 3. Almost 300 Rev–host protein interactions have been reported in the NCBI HIV-1 interaction database. Of these interactions, many cofactors appear to be
nucleic acid binders, as shown by GO slim terms. In the second panel, the type of interaction reported is listed alongside the most reported proteins. Most of these
cofactors are simply reported to interact with Rev, though some are known to be inhibitors or enhancers, etc. The third panel explores the interactions of 25 reported
Rev cofactors, listing their known GO molecular functions, biological processes and cellular compartments in more detail.
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Rev expressed from an HIV-1 provirus (fully infective HIV-1
construct or replicons), ideally tagged to facilitate biochemi-
cal characterization under stringent conditions. The use of
chimeric HIV-1 viruses or replicons allows experiments to
be performed in more physiological models such as T CD4
lymphocytic lines and primary cells. Such an approach
would ensure that Rev and its HIV-1 RNA substrates are pro-
duced at physiological levels and in the correct stoichiometry.Despite the challenges of uniting various interactome
data, there is a set of proteins identified consistently in a
number of different studies, imbuing them with credibility
[117,123,124]. The known Rev interaction network is explored
in figure 3, showing which types of interaction have most
often been identified and the GO molecular functions of the
interactors. The evidence behind the interaction of some of
these widely reported Rev factors is discussed below.
Table 1. Technical challenges.
experimental
consideration technical challenge experimental compromise experimental issue
Rev is an RNA-binding
protein
Rev can establish strong
interaction with RNA
RNase treatment is critical to
differentiate direct from indirect
interactions in protein–protein
interaction analysis
Rev can be co-purified with proteins that do not
interact directly with it through RNA bridges;
hence, protein–protein interaction studies
lacking RNases should be considered against
this background
Rev gene is entirely
overlapped by other
viral genes
(figure 1a)
Rev is, therefore, difficult to
genetically manipulate, to
clone or tag, in the context
of a replicon or virus
full length or selected regions of
Rev are often ectopically
expressed and, in several cases,
it is not co-expressed with HIV-1
RNA
ectopic expression may result in artificial
localization and non-physiological expression
levels
expression of select motifs may lead to non-
native folding conformations and behaviour
Rev function relies on its multimerization of HIV-
1 RNA; in the absence of HIV-1 RNA, Rev are
may thus assemble in non-physiological
complexes; moreover, Rev and underspliced
HIV-1 RNA are at a given stoichiometry that
is difficult to recapitulate using plasmids
Rev is a low abundant
HIV-1 protein
Rev is difficult to pull down
and isolate at sufficient
concentration for
biochemical characterization
Rev is typically overexpressed Rev expression at non-physiological levels is
likely to lead to non-native behaviour
without co-expression of the viral RNA under
physiological stoichiometry, Rev may establish
artificial interactions
antibodies available against Rev do not allow
efficient and selective immunoprecipitation;
hence, tags might be required
HIV-1 infects and
propagates in CD4+
lymphocytic cells
T-lymphocytes are difficult to
transfect
Rev is typically expressed in
uninfected non-relevant cell lines
(e.g. HEK293T, HeLa), and cell
extracts
the proteome of a CD4- cell is expected to differ
from that of a CD4+ lymphocytic counterpart;
hence, Rev may establish non-physiological
interactions in HIV-1 unrelated cell lines
HIV-1 infection also causes a profound
remodelling of the cell proteome and
transcriptome; hence, Rev complexes detected
in uninfected conditions might be non-
functional or just not exist in infected cells
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DEAD (Asp–Glu–Ala–Asp)/H box RNA helicases have
been functionally implicated in all steps of RNA metabolism
as well as ATP-dependent RNA duplex unwinding. Several
DEAD/H box proteins interact with Rev, most prominently,
DDX1. DDX1 was initially identified to bind a motif of Rev
in yeast-two hybrid screens and then confirmed to interact
with Rev using protein overexpression and co-immunopreci-
pitation [62,125]. DDX1 silencing reduced the expression of
Gag from a Gag–RRE expression vector by greater than
85% in the presence of Rev, signifying that DDX1 maypromote Rev–RNA export [62]. The observation of Rev–
RRE binding using total internal reflection microscopy and
mobility shift assays confirmed this, revealing that DDX1
enhances higher-order Rev/RRE stoichiometries [41,42].
Although no strict functional mechanism is yet determined,
a recent model acknowledging these data proposed that
DDX1 may act as an RNA chaperone, remodelling stem IIB
of the RRE to facilitate Rev binding [42]. DDX3 is another
DEAD/H box helicase linked to HIV-1: it is a nucleocytoplas-
mic shuttling protein able to co-precipitate both Rev and
royalsocietypublishing.org/journal/rsob
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RNA/RanGTP/CRM1 complex export [126]. Indeed,
knock-out of endogenous DDX3 can suppress RRE–RNA
export 13-fold in a Rev-dependent manner, as measured by
Gag expression [126]. Importantly, this effect is not observed
when the RRE is replaced with a different transport element.
Additionally, Northern blotting analysis showed that DDX3
significantly increased levels of gagpol mRNA in the cyto-
plasm transcribed from a Gagpol-RRE expression vector,
confirming that it influences Rev-dependent RNA export
[126]. Other helicases, including DDX5, DDX17 and
DDX21, interact with Rev and enhance Rev-mediated RNA
export [127,128]. It is thus plausible that these helicases
cross-talk to influence viral RNA export cooperatively. The
exact functional mechanisms underpinning Rev regulation
by helicases, however, await discovery.
CRM1 was one of the earliest Rev interactors identified. It
was initially shown to bind Rev through separation of
nuclear envelope proteins by gel electrophoresis, followed
by treatment with radiolabelled Rev protein [129], which
revealed a band of approximately 110 kDa. Similarly, the
radioactively labelled Rev NES was incubated in cell extracts
and interacting proteins were eluted and separated by gel
electrophoresis, which also highlighted an approximately
110 kDa band, suggesting that this unknown protein could
bind Rev at its NES. This ‘p110’ mysterious protein was
later identified as an exportin, named CRM1 [130], which is
inhibited by leptomycin B [131]. This novel association
linked Rev to a nuclear translocation system for the first
time and began to reveal the mechanics of Rev transactiva-
tion. Elegant experiments by Fukuda et al. [130] expressing
the NES peptide of Rev in the nuclei of fibroblasts revealed
that it was rapidly exported to the cytoplasm. Cells pre-trea-
ted with leptomycin B, however, inhibited this nuclear
export, corroborating the notion that CRM1 was probably
responsible for Rev translocation across the nuclear pore.
Mutations of the homologue Crm1p in yeast were similarly
shown to reduce Rev transactivation activity. Moreover, the
ability of Crm1p to interact with both nuclear pore proteins
and Rev was reported in this system, providing further evi-
dence that CRM1 guides Rev across the nuclear envelope
[132]. Interestingly, Ristea et al. [133] found that Rev and
CRM1 colocalize in the nucleolus. This colocalization is
dependent on a functional Rev NES, suggesting that both
proteins are directly interacting. In the same study, overex-
pression of CRM1 appeared to reduce Rev-mediated
RRE(+)–RNA export in a dose-dependent manner, which
the authors suggest may occur due to CRM1 sequestering
Rev in the nucleolus. It is notable, however, that overex-
pressed CRM1 is dislocated, and this aberrant distribution
might be the cause Rev of dysfunction.
Eukaryotic Initiation Factor 5A (eIF5A) is an essential
protein that facilitates translation elongation of polyproline
regions and prevents ribosomal stalling [134]. It can bind
specifically to the NES of Rev [135,136]. Non-functional
eIF5A mutants that retain the ability to bind Rev hamper
the export of Rev–CRM1 complexes to the cytoplasm
[135,137]. Indeed, T CD4 lymphocytic cell lines overexpres-
sing these mutants failed to sustain HIV-1 replication
efficiently [136]. A pool of eIF5A localizes at the periphery
of the nuclear pore complex [137] and has been found to
interact with nucleoporins [60]. Moreover, recombinant
GST-Rev protein export to the cytoplasm was abrogated byusing antibodies against eIF5A [138]. Taken together, these
data suggest that eIF5A plays a critical role in the Rev/
CRM1-mediated export of HIV-1 underspliced RNAs. How-
ever, several groups failed at confirming the existence of an
interaction between EIF5A and Rev [21,139], and thus
whether this complex plays a physiological role in HIV-1
infection remains controversial.2.9. Rev and its interactions with cofactors are HIV-1
drug targets
Rev is critical for HIV-1 gene expression and, therefore,
represents a potential anti-viral target. Despite this, there
are currently no Rev-based therapeutics in clinical use. It
has long been known that dominant negative mutants of
Rev can abrogate wild-type Rev function in lymphocytic
cells [140,141]. For example, ‘Rev M10’ contains two point
mutations in the Rev NES which completely abrogates its
transactivation function, while competing with wild-type
Rev for binding to the RRE [48]. M10 has been investigated
in clinical trials [142–144]. However, it is challenging to deli-
ver into cells, and resistant strains of HIV-1 with altered RREs
arose after constitutive M10 expression [145].
Other therapeutic approaches target the Rev/RRE inter-
action itself using small molecules. An early iteration of this
approach used aminoglycoside antibiotics which specifically
bound to the RRE at the Rev-binding site [146], blocking
Rev’s interaction and inhibiting HIV-1 gene expression
[147]. Since then, a series of small molecules able to inhibit
Rev/RRE association have been reported, including amino-
glycosides, antisense nucleic acids [148,149], synthetic
diphenylfuran cations [150,151], RNA aptamers [152,153],
metallopeptides [154,155] and several pre-existing drug com-
pounds [156]. Several of these agents bind to the RRE
synonymously to Rev, inserting basic regions into the same
wobble-base groove in the RRE. Peptide ligands have been
developed which similarly adopt the same α-helicity as the
Rev ARM; in some cases, these ligands are able to bind to
the RRE with higher affinity than Rev itself (about sevenfold)
and can successfully block HIV-1 replication [157–161]. Other
small molecules, including 8-azaguanine, suppress viral gene
expression by redirecting localization of Rev to the cyto-
plasm, impairing its function [162]. While these agents are
anti-viral, off-target effects often render them toxic for
human cells. Moreover, those that rely on structure specificity
inadvertently apply a selection pressure for RRE and Rev,
leading to mutations that provide resistance [163]. It also
remains challenging to deliver these treatments to target cells.
As CRM1 is required to escort RNA-bound Rev across the
nuclear envelope, blocking the CRM1/Rev interaction is a
potential anti-viral opportunity. It is well established that
CRM1-inhibiting drugs, such an anti-fungal agent leptomy-
cin B, can restrict HIV-1 replication [131,164]. However,
CRM1 typically exports host proteins and is instrumental
for exporting ribosomal subunits (for a comprehensive
review, the reader is pointed to Okamura et al. [165]). There-
fore, CRM1 inhibition affects downstream targets and the
cellular environment and, indeed, leptomycin B is toxic to
human cells. However, small molecular inhibitor KPT-185
was able to restrict both HIV-1 replication and AIDS-induced
primary effusion lymphoma in primary cells by blocking
Rev/CRM1 interactions [166] and elicited cytotoxic effects
Naji et al.
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Figure 4. The overlap of host proteins identified to interact with Rev from three
available datasets discovered using IP and MS. For Naji et al. [111], the top 250
candidates were considered as cited in the paper; for Jager et al. [114], proteins
from both cell types were considered. For Arizala et al., reported proteins were
royalsocietypublishing.org/journal/rsob
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10only at concentrations 850-fold higher than the active
concentration [166].
Targeting other Rev–host cofactor interactions is similarly
difficult but not impossible: Campos et al. developed ABX464
[167], a drug that restricts HIV-1 replication in mice. ABX464
binds to and stabilizes the CBC complex, enhancing RNA
export by the TREX export pathway of fully spliced RNAs,
antagonizing Rev posited inhibition of this pathway [63].
Importantly, while it changes the levels of spliced/unspliced
viral RNA, ABX464 does not affect cellular RNA [167]. It has
since completed three phase II clinical trials and has success-
fully restricted HIV-1 replication in vivo. This highlights the
importance of reproducibly defining the Rev interactome: it
may unlock dozens of potential therapeutic targets.normalized to HGNC IDs using the R package biomaRt [120] and pseudogenes/
proteins which could not be mapped were filtered out.
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3.1. The native Rev interactome remains unknown
The role of Rev in RNA trafficking was identified shortly after
its discovery in 1986; in the subsequent 30 or more years of
research, Rev has continued to pose more questions than
answers. For example, we have discussed here the known
cofactors of this elusive protein, though the reader may
note that much of this research is ‘correlative’ with the under-
lying molecular mechanism remaining unknown. As Rev is a
difficult protein to study (table 1), the number of Rev–host
protein interactome studies is limited, and those available
have been defined under a broad range of conditions and cri-
teria. It is, therefore, difficult to list interactors validated
under common physiological environments. As aforemen-
tioned, the overlap between these datasets is low (figure 4).
Some researchers have used an approach to examine which
host proteins are involved in Rev’s RNA export function by
capturing the singly or unspliced viral RNA and using MS
to examine which proteins are bound [59,121,122]. These
studies may also reveal Rev-binding partners. Consideration
of these protein datasets corroborate some of the unshared
host proteins reported in Rev protein–protein studies, indicat-
ing that candidate proteins identified can be true interactors
despite the limited overlap between datasets. For example,
approximately 30% of the proteins found by Marchand
et al. [114] are also reported by Naji et al. [111]. However,
the overlap between these datasets remains modest, and the
problem of varying experimental conditions persists.
3.2. There is no known function behind Rev nucleolar
localization
While Rev participates in nucleocytoplasmic shuttling, it also
displays a well-documented tendency to localize in the
nucleolus [22,48,120,125,168,169], which is currently unex-
plained. This has recently been suggested to arise from
masking of the NES, as mutation of the NES constrains Rev
to the nucleolus. Moreover, Behrens et al. [170] have shown
that deliberate masking and unmasking of the NLS is able
to alter this phenotype. Though the function behind this
nucleolar residence is undetermined, Rev mutants that do
not localize in the nucleolus are impaired in their ability to
export viral RNA [120,168], suggesting it is critical to theRev functional cycle. Reinforcing this idea, FRET measure-
ments also suggest that Rev dimerization occurs in the
nucleolus [171]. Additionally, when Rev and CRM1 are over-
expressed separately, they yielded nucleolar and nuclear
envelope localization, respectively [166]. However, when
both were overexpressed together, CRM1 mobilized to the
nucleolus in a Rev-dependent manner. These results suggest
that the nucleolus may be an interaction point for both pro-
teins [166]. The roles of Rev nucleolar localization remain
under intensive investigation.
3.3. The Rev C-terminal domain is structurally
unresolved
Some of the challenges of working with Rev have been solved
thanks to recent technological advances. For example, Rev
tends to aggregate and precipitate [172], and these properties
have represented a challenge to resolve its structure [12,172].
In fact, it took 14 years after the initial Rev–RNA NMR
models [27] until the first crystal structures of Rev were
resolved [11,14]. Thanks to advances in crystallography tech-
nologies, the field has since reported invaluable crystal
structures of Rev [12,47] and even RRE-bound Rev dimers
[13] which have massively contributed to our understanding
of the Rev–RRE interaction. However, the Rev CTD still
remains mysterious due to its structural plasticity that
forces researchers to either delete it or leave this region unre-
solved in order to obtain structural information [12]. Recent
mutagenesis research suggests that the CTD may help stabil-
ize Rev and prevent aggregation [173]. Conversely, an
increase in HIV-1 fitness is observed when stop codons are
included in the CTD, suggesting it may play an inhibitory
role [174]. More work must be carried out to resolve the mol-
ecular function of the CTD. As the structural biology field
continues to advance, more structures will emerge, and
these will probably provide an unprecedented view on the
interactions orchestrated by Rev.4. Conclusion and future perspectives
Much is known about the HIV-1 Rev protein, particularly of
its essential role in RNA export. However, many questions
remain unsolved. It is thus vital that systems and method-
ologies are established which strive to more closely emulate
royalsocietypublishing.org/
11natural HIV-1 infection and native Rev activity when eluci-
dating the unknowns. These improved approaches will
hopefully advance us towards understanding the structure,
functions and interactions of the HIV-1 Rev protein. In
turn, a better understanding of Rev biology will probably
open novel therapeutic avenues on the quest to combat
HIV-1 infection.
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